Silicone Band Versus Prilocaine Spray for Lifelong Premature Ejaculation
A Frenular Silicone Band for Lifelong Premature Ejaculation: A Randomized Controlled Pilot Trial of Preliminary Efficacy, Tolerability, and Patient Satisfaction
1 other identifier
interventional
32
1 country
1
Brief Summary
This pilot study compared two approaches for men with lifelong premature ejaculation, a condition in which ejaculation occurs sooner than desired from the first sexual experiences and is difficult to delay. The aim was to explore their effects on ejaculation time, symptoms, treatment satisfaction, and side effects, and whether improvements persisted after treatment stopped. Thirty-two men aged 18-35 years were assigned by chance to use either a soft silicone band over the frenulum, the sensitive area on the underside of the head of the penis, or a prilocaine spray, a medicine that temporarily reduces sensation. Both treatments were used before or during intercourse as instructed for one month. Both groups also received guidance on techniques to help control ejaculation, including pausing stimulation and relaxation exercises. After the first month, participants stopped using the band or spray and continued the behavioural techniques alone for another month. Assessments took place at the start of the study and after one and two months. Participants estimated their average time from vaginal penetration to ejaculation and completed a questionnaire about premature ejaculation symptoms. Treatment satisfaction, treatment experience, and side effects were also assessed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 15, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
January 15, 2026
CompletedFirst Submitted
Initial submission to the registry
September 10, 2026
CompletedFirst Posted
Study publicly available on registry
September 15, 2026
CompletedSeptember 15, 2026
September 1, 2026
3 months
September 10, 2026
September 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Change From Baseline in Premature Ejaculation Diagnostic Tool (PEDT) Score
Change from baseline in the total PEDT score at the end of Month 1 and Month 2. The PEDT is a five-item questionnaire assessing ejaculatory control, frequency of premature ejaculation, ejaculation with minimal stimulation, distress, and interpersonal difficulty. Each item is scored from 0 to 4, yielding a total score of 0 to 20. Higher scores indicate more severe symptoms; a reduction from baseline indicates improvement. Month 1 assessed response during the assigned intervention plus behavioral therapy, and Month 2 assessed response after intervention withdrawal while behavioral therapy continued.
Baseline, Month 1, and Month 2
Change From Baseline in Patient-Estimated Intravaginal Ejaculatory Latency Time (IELT)
Change from baseline in patient-estimated IELT, measured in minutes, at the end of Month 1 and Month 2. IELT was defined as the time from vaginal penetration to ejaculation. At each visit, participants recalled their average IELT over the preceding two weeks, rounded to the nearest minute. No stopwatch or intercourse diary was used. Higher values indicate longer ejaculatory latency. Month 1 assessed response to the assigned intervention plus behavioral therapy; Month 2 assessed persistence of response after withdrawal of the assigned intervention, with behavioral therapy continuing alone.
Baseline, Month 1, and Month 2
Study Arms (2)
Frenular Silicone Band Plus Behavioral Therapy
EXPERIMENTALParticipants used a frenular silicone band during each vaginal intercourse encounter for one month and received behavioral counselling. The band was discontinued after the first month, while behavioral techniques continued for a second month.
Prilocaine Spray Plus Behavioral Therapy
ACTIVE COMPARATORParticipants used topical prilocaine 10% spray before each vaginal intercourse encounter for one month and received behavioral counselling. The spray was discontinued after the first month, while behavioral techniques continued for a second month.
Interventions
A single-use segment measuring 4 cm × 2 cm and 2 mm thick was cut from medical-grade silicone adhesive tape intended for wound contact. Once a full erection was achieved, the participant positioned the band over the ventral frenular region, leaving the remainder of the glans exposed. The band remained in place throughout intercourse and was removed immediately afterward. A fresh segment was used for each encounter during the first month. Participants received standardized application and removal training. The tape was used outside its stated intended purpose.
Prilocaine 10% spray was applied to the glans penis approximately 5 minutes before each vaginal intercourse encounter during the first month. Participants received standardized instructions on application. The spray was discontinued at the end of the first month.
Eligibility Criteria
You may qualify if:
- Male participants aged 18-35 years.
- Lifelong (primary) premature ejaculation with a reported inability to delay ejaculation.
- Premature Ejaculation Diagnostic Tool (PEDT) score of 11 or higher.
- In a stable heterosexual relationship for at least six months.
- Able to engage in vaginal intercourse at least three times per week.
- Willing to comply with the study protocol and provide written informed consent.
You may not qualify if:
- Secondary (acquired) premature ejaculation.
- Erectile dysfunction, defined as a five-item International Index of Erectile Function (IIEF-5) score below 22.
- Any chronic systemic disease, including diabetes mellitus or hypertension.
- Any psychiatric disorder or current or recent use of psychiatric medications.
- Regular use of medication affecting ejaculatory function.
- Use of any treatment for premature ejaculation at enrollment.
- Known hypersensitivity to prilocaine or silicone-based materials.
- Any penile anatomical abnormality.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Başakşehir Çam and Sakura City Hospital, Department of Urology
Istanbul, Istanbul, 34200, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD VEYSEL SEZGİN
Study Record Dates
First Submitted
September 10, 2026
First Posted
September 15, 2026
Study Start
September 15, 2025
Primary Completion
December 15, 2025
Study Completion
January 15, 2026
Last Updated
September 15, 2026
Record last verified: 2026-09
Data Sharing
- IPD Sharing
- Will share
- Access Criteria
- Researchers may request access by contacting the corresponding author at \[veyselsezgin1@gmail.com\](mailto:veyselsezgin1@gmail.com) and submitting a proposal describing the research question, requested data, and planned analyses. Requests will be assessed for scientific relevance and consistency with participant consent and institutional requirements. Approved researchers will receive only the de-identified data needed for the agreed purpose, subject to a data use agreement prohibiting participant re-identification and unauthorized redistribution.
De-identified individual participant data underlying the published results will be made available upon reasonable request to the corresponding author. These data will include treatment allocation, baseline characteristics, IELT estimates and PEDT scores at each assessment, PETO scores, treatment satisfaction scores, and recorded adverse events. Direct identifiers will not be shared, and potentially identifying information will be removed or generalized to protect participant confidentiality.